Dr. Kevin Wang's team at Princess Margaret Cancer Centre in Toronto just received $50,000 to crack one of the hardest problems in cancer medicine: why immunotherapy, a treatment that has saved countless lives in other cancers, fails almost entirely in brain tumours.
The answer may lie in something called the "cold" immune microenvironment—a hostile pocket of cellular machinery that brain tumours create to keep immune cells at a distance. Brain Cancer Canada, the country's only fully volunteer-driven charity dedicated exclusively to brain cancer research, awarded the funding through the Dwayne Andrews Glioblastoma Research Grant, honouring the brother of Kevin Andrews, CEO of Auto|One Group, who died from glioblastoma.
The research focuses on a specific and devastating form of the disease: IDH-mutant gliomas, which drive many brain tumours in adolescents and young adults aged 15 to 39. These tumours often start slowly but become more aggressive over time, and currently offer few treatment options. What makes this project urgent is its translational focus—the researchers aren't just asking why immunotherapy fails; they're systematically mapping the cell-by-cell changes that occur in these tumours to identify treatments that could reverse the immune suppression and potentially unlock a whole new class of therapies.
"Our goal is to unlock more effective and less toxic treatments for patients and families facing this devastating disease," Dr. Wang said of the research program. The team will build a detailed cellular picture of how IDH-mutant gliomas evolve and create their immunosuppressive environment, then test whether specific drugs might flip the switch and restore immune function. If successful, this work could identify candidates for clinical trials—concrete pathways toward treatments that don't yet exist for this population.
What makes this grant announcement particularly significant is the context: Brain Cancer Canada awarded $425,000 across six grants during May's Brain Cancer Awareness Month. This single award represents a crucial investment in an area where, as Dr. Wang noted, "urgent clinical need far exceeds available support." For young patients with glioblastoma, where standard options are limited and aggressive, the difference between "available" and "possible" could be everything.
The funding also reflects a personal commitment. Auto|One Group has donated over $300,000 to Brain Cancer Canada over four years, making them the charity's largest donor on record. Kevin Andrews created the Dwayne Andrews Glioblastoma Research Grant in memory of his brother, who lost his battle with the disease. "What makes Dr. Wang's work so meaningful is its focus on changing what's possible for patients, helping to open the door to treatments that, until now, have not been within reach," Andrews said. "Everyone deserves that chance, one my brother never had."
The research represents a concrete step toward rewriting that story for the next generation of young patients diagnosed with IDH-mutant gliomas. By mapping the immune microenvironment cell by cell and testing ways to reverse the tumour's immunosuppressive tricks, Dr. Wang's team may uncover the keys that unlock immunotherapy for a disease that has long resisted it. In cancer research, that kind of breakthrough—moving from "why it doesn't work" to "how we might make it work"—can reshape a patient's entire prognosis.